Participation in B. Riley Securities Radiopharma Conference
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
23 FEBRUARY 2024
RAD to participate in B. Riley Securities Radiopharma Investor Conference
Sydney, Australia – 23 February 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the
“Company”), a clinical-stage biopharmaceutical company focused on developing innovative
radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that the
Company has been invited to present at the B. Riley Securities Radiopharma Investor Conference, to
be held on 1 March 2024.
The event will take place in New York and features 15+ small-to-mid cap public and private biotech,
medtech, medical services, CDMO (contract development & manufacturing organisation), and
industrial companies focused on bringing life-saving radiotherapeutics and imaging agents to the
market.
A range of US institutional and professional investors will see Radiopharm management deliver a
dedicated presentation on the Company, as well as being part of a panel discussion regarding
imaging in radiopharmaceuticals.
A copy of the RAD presentation will be released in conjunction with the conference.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021.
The company has a pipeline of six distinct and highly differentiated platform technologies spanning
peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical
stages of development from some of the world’s leading universities and institutes. The pipeline has
been built based on the potential to be first-to-market or best-in-class. The clinical program includes
one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and
brain. Learn more at Radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
ASX ANNOUNCEMENT
23 FEBRUARY 2024
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Share your feedback
Discover